KR900000092A - 신경 장애의 치료에 있어서 유리딘의 약리학적 용도 - Google Patents

신경 장애의 치료에 있어서 유리딘의 약리학적 용도 Download PDF

Info

Publication number
KR900000092A
KR900000092A KR1019890008467A KR890008467A KR900000092A KR 900000092 A KR900000092 A KR 900000092A KR 1019890008467 A KR1019890008467 A KR 1019890008467A KR 890008467 A KR890008467 A KR 890008467A KR 900000092 A KR900000092 A KR 900000092A
Authority
KR
South Korea
Prior art keywords
uridine
agent
treatment
disorder
caused
Prior art date
Application number
KR1019890008467A
Other languages
English (en)
Inventor
데 루카 지오반나
디 스타지오 지오반니
마레라찌 마이로
폴리티 빈센조
Original Assignee
마리오 마레라찌
폴리파르마 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마리오 마레라찌, 폴리파르마 에스.피.에이. filed Critical 마리오 마레라찌
Publication of KR900000092A publication Critical patent/KR900000092A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

신경 장애의 치료에 있어서 유리딘의 약리학적 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 유리딘으로 되는 파킨슨병 치료용 약제.
  2. 제1항에 있어서, 파킨슨병의 증후군의 차단제인 약제.
  3. 신경이완제와 함께 유리딘으로 되는, 정신분열증 치료용 약제.
  4. 제3항에 있어서, 상기 신경이완제가 할로페리돌인 약제.
  5. 뇌 도파민계의 기능 변화로 인한 장애를 치료하기 위한, 유리딘으로 되는 약제.
  6. 제5항에 있어서, 상기 장애가 뇌 조직에서의 도파민 방출이 변화됨에 기인하는 병임을 치료하는 약제.
  7. 제6항에 있어서, 상기 장애가 뇌 조직에서 콜레시스토키닌의 저농도에 기인하는 병임을 치료하는 약제.
  8. 제5항에 있어서, 뇌에서의 콜레시스토키닌을 증가시키는, 뇌 장애의 치료용 약제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890008467A 1988-06-21 1989-06-20 신경 장애의 치료에 있어서 유리딘의 약리학적 용도 KR900000092A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT48118A/88 1988-06-21
IT48118/88A IT1219667B (it) 1988-06-21 1988-06-21 Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico

Publications (1)

Publication Number Publication Date
KR900000092A true KR900000092A (ko) 1990-01-30

Family

ID=11264638

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890008467A KR900000092A (ko) 1988-06-21 1989-06-20 신경 장애의 치료에 있어서 유리딘의 약리학적 용도

Country Status (8)

Country Link
US (1) US4960759A (ko)
EP (1) EP0348360B1 (ko)
JP (1) JPH0623109B2 (ko)
KR (1) KR900000092A (ko)
AT (1) ATE100322T1 (ko)
CA (1) CA1327003C (ko)
DE (1) DE68912419T2 (ko)
IT (1) IT1219667B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634374B1 (fr) * 1988-07-19 1993-10-15 Laboratoires Serobiologiques Agents photoprotecteurs, cytophotoprotecteurs cutanes ayant une activite photoprotectrice des cellules constitutives, fonctionnelles de la peau, en particulier des cellules de langerhans, a base de composes nucleiques : nucleoprotides, ribonucleotides et desoxyribonucleotides, ribonucleosides et desoxyribonucleosides, compositions cosmetiques ou dermo-pharmaceutiques contenant un tel agent ainsi que des nouveaux composes en soi
JP3459013B2 (ja) * 1993-05-19 2003-10-20 株式會社緑十字 ウリジンを有效成分とする關節炎治療剤
US5962459A (en) * 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
IT1290781B1 (it) * 1996-05-28 1998-12-10 Polifarma Spa Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US20060069061A1 (en) * 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
EP1140104B1 (en) 1998-07-31 2007-09-26 Massachusetts Institute of Technology Treatment of alzheimer's disease by increasing cytidine levels in vivo
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
PT1171137E (pt) 1999-02-23 2008-03-17 Univ California Utilização de triacetiluridina para o tratamento de perturbações mitocondriais
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
US6727231B1 (en) 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
AUPR951101A0 (en) 2001-12-13 2002-01-24 Centre For Molecular Biology And Medicine Method of treatment
EP1727554A4 (en) * 2003-10-08 2009-09-30 Mclean Hospital Corp METHODS OF TREATING PSYCHIATRIC DISORDERS, ALCOHOL AND DRUG ABUSE DISORDERS, AND OTHER DISORDERS USING COMBINATIONS CONTAINING OMEGA 3 FATTY ACIDS
WO2005112635A2 (en) * 2004-05-13 2005-12-01 Massachusetts Institute Of Technology Uridine effects on dopamine release
WO2007060886A1 (ja) * 2005-11-24 2007-05-31 National University Corporation Hokkaido University 神経変性疾患治療薬
EP1897937A1 (en) * 2006-09-07 2008-03-12 NeuroProgen GmbH Leipzig Method of culturing NPCs
US8551452B2 (en) 2007-11-02 2013-10-08 Massachusetts Institute Of Technology Uridine dietary supplementation compliance methods and use thereof
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
US9192605B2 (en) 2009-07-31 2015-11-24 Clera Inc. Compositions and methods for treating parkinson's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1178044B (it) * 1984-10-09 1987-09-03 Polifarma Spa Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
JPH0669953B2 (ja) * 1985-08-16 1994-09-07 日産化学工業株式会社 脳脊髄系神経栄養剤
AU2789989A (en) * 1987-10-28 1989-05-23 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof

Also Published As

Publication number Publication date
EP0348360A2 (en) 1989-12-27
ATE100322T1 (de) 1994-02-15
DE68912419T2 (de) 1994-08-04
JPH0623109B2 (ja) 1994-03-30
EP0348360B1 (en) 1994-01-19
JPH0245425A (ja) 1990-02-15
EP0348360A3 (en) 1991-10-23
CA1327003C (en) 1994-02-15
IT8848118A0 (it) 1988-06-21
DE68912419D1 (de) 1994-03-03
US4960759A (en) 1990-10-02
IT1219667B (it) 1990-05-24

Similar Documents

Publication Publication Date Title
KR900000092A (ko) 신경 장애의 치료에 있어서 유리딘의 약리학적 용도
BG99885A (en) Pyrene-pyridine derivatives
KR920019342A (ko) 골질환 치료제
KR910004187A (ko) 세트랄린을 사용한 조기사정의 치료방법
KR950700060A (ko) 운동 뉴우런 질병의 치료에 유용한 약품을 얻기 위한 2-아미노-6-트리플루오로메톡시 벤조티아졸(리루졸)의 사용(Application of 2-amino 6-trifluoromethoxy benzothiazole(riluzole) for obtaining a drug useful in the treatment of motor neuron diseases)
LU91926I2 (fr) Belimumab et ses dérivés pharmaceutiquement acceptables (Benlysta®)
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
AR016217A1 (es) Composicion farmaceutica que comprende un modulador dispositivo de un agonista receptor nicotinico, metodo para el tratamiento de un trastorno asociado conuna transmision reducida de nicotina, metodo para identificar un agonista repector nicotinico, uso de un modulador positivo de un agonista recept
KR930012022A (ko) 뇌조직 보호용 모다피닐(Modafinil)
FR2793678B1 (fr) Manchon elastique a garniture viscoelastique pour la protection ou le soin de doigts ou d'orteils
ATE160779T1 (de) Antipsychotische indazolderivate
KR920016088A (ko) 하부 요로 질환의 치료
KR890011589A (ko) 벤즈아미드의 용도
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
KR950701820A (ko) 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
KR970703763A (ko) 간 재생용 치료제(therapeutic agent for liver regeneration)
ATE141796T1 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
KR940008678A (ko) 주사용 메스나 액제
FI945446A (fi) Kotiinin käyttö tupakan vieroitusoireyhtymän lievittämiseksi
KR900012622A (ko) 피부질환치료 조성물
DE69011857T2 (de) Verwendung von GnRH-analog zur Herstellung eines Arzneimittels zur Behandlung von Motilitätsstörungen.
KR900017587A (ko) 바이러스 감염증 치료제의 제조를 위한 티아졸 유도체 티프로티모드의 용도
IT1247476B (it) Derivati della cumarina.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid